What Actually Happens When We Try to Eliminate Demand.
Up to now, we’ve been talking in patterns.
How people behave.
How punishment adapts behaviour rather than removing it.
How costs move rather than disappear.
So let’s stop hovering above the map and pick somewhere concrete.
Drugs.
Not because they’re unique — but because they’re familiar. And because if this logic doesn’t hold here, it probably doesn’t hold anywhere.
First question: what problem are we actually trying to solve?
When we talk about “the drugs problem”, what do we mean?
Is it:
- that substances exist?
- that people use them at all?
- that some people become dependent?
- or that harm occurs — to users and others?
Because those are very different problems.
And it’s worth being honest: we often slide between them without noticing.
The idea we keep coming back to
Again and again, policy returns to a reassuring thought:
If we make drugs illegal enough, people will stop using them.
And if they don’t stop?
Well… maybe enforcement hasn’t gone far enough yet.
That idea feels neat.
It feels decisive.
It feels like control.
But at this point it’s also worth asking:
Has it actually worked that way?
So what’s actually happened?
Despite decades of prohibition, criminalisation, and enforcement:
- drugs haven’t disappeared
- demand hasn’t gone away
- and new substances keep turning up
So something else must be going on.
Because if the theory were right, we should have seen steady decline by now.
Instead, what we’ve seen is adaptation.
Hold on — adaptation by who?
Not just users.
Supply adapts too.
And when supply is criminalised, the incentives change very quickly.
If moving large quantities is risky, what’s the obvious response?
You move less, but make it stronger.
Why drugs tend to get stronger, not weaker
This bit often surprises people.
Under prohibition, suppliers are pushed towards substances that are:
- more potent
- easier to conceal
- harder to detect
- and quicker to sell
That’s not ideology.
It’s logistics.
Which is why drug markets tend to shift:
- away from bulkier, lower-potency substances
- towards smaller, stronger, more concentrated ones
So even if overall usage stays flat, the risk per use goes up.
That’s not accidental.
It’s exactly what the incentives encourage.
A quick pause — does that ring any bells?
Because once you see it here, it’s hard not to see it elsewhere.
We didn’t get safer drugs by banning them harder.
We got less predictable drugs.
Higher overdose risk.
Unclear dosages.
No quality control.
And then we act surprised when harm increases.
The UK story we don’t talk about much
It’s easy to forget this wasn’t always framed purely as a criminal issue in the UK.
There was a period when drug use was treated more explicitly as a health problem — something to be managed, treated, and reduced rather than eradicated.
Over time, that framing shifted.
And here’s the key question:
What changed when we leaned harder into punishment?
Did drugs disappear?
Or did regulation disappear?
New drugs, same old pattern
When one substance becomes harder to obtain, another appears.
Sometimes synthetic.
Sometimes much stronger.
Often less understood.
From highly potent cannabis strains, to synthetic cannabinoids, to diverted pharmaceuticals — the same cycle keeps repeating.
Clamp down here → something riskier pops up there.
The market moves faster than the law.
It always has.
So who actually carries the risk?
Here’s where this stops being abstract.
People with money:
- find safer supply
- avoid enforcement
- access treatment quietly
People without money:
- take bigger risks
- use more unpredictable substances
- absorb the consequences
So the harm doesn’t disappear.
It concentrates.
And once again, not because anyone intended it to — but because that’s how the system rewards adaptation.
And the cost?
We usually talk about drug policy costs in very narrow terms.
Policing.
Courts.
Prisons.
But the heavier costs land elsewhere:
- emergency healthcare
- long-term treatment
- mental health services
- social care
- lost productivity
When those systems strain, we call it “pressure”.
We rarely trace that pressure back to the choices that helped create it.
So let’s ask a slightly different question
Not:
“How do we finally win the war on drugs?”
But:
“What outcome are we actually trying to achieve?”
Less use?
Less harm?
Fewer deaths?
Lower cost?
Because if harm reduction, stability, and cost control are the goals, decades of evidence suggest that purely punitive approaches are a very expensive way of missing them.
And no — this isn’t about approval
This is usually the point where someone says:
“So are you saying drugs are fine?”
No.
Questioning punishment isn’t endorsement.
It’s recognising that:
- demand exists
- markets adapt
- and harm increases when regulation disappears
The choice isn’t between “being tough” and “giving up”.
It’s between:
- managing a persistent reality
- or repeatedly paying for the consequences of pretending it isn’t one
Why this example matters
Drugs aren’t an exception.
They’re a case study.
They show us — very clearly — what happens when:
- behaviour persists
- punishment escalates
- incentives are ignored
- and harm is treated as moral failure rather than system design
And once you’ve seen that pattern here, it becomes very hard not to spot it elsewhere.
Which is exactly where we’re going next.
Next up, we’ll take this same lens somewhere equally uncomfortable:
sex work — and what happens when policy pushes vulnerability out of sight instead of reducing it.
(Hold on to your pint. Onwards.)
Further reading & evidence (for those who want it)
This post isn’t arguing for approval, permissiveness, or ideology. It’s drawing on a large body of public-health, criminology, and policy research that has examined what actually happens when drug use is managed primarily through punishment rather than regulation or treatment.
For anyone who wants to explore the evidence behind the patterns discussed above, the following sources are a good place to start:
Drug use, harm, and policy outcomes
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Extensive comparative research on drug use trends, harm, potency, and the effects of different policy approaches across Europe. - World Health Organization (WHO)
Public-health framing of substance use, harm reduction, treatment effectiveness, and population-level outcomes. - The Global Commission on Drug Policy
Reports examining decades of drug enforcement, market adaptation, unintended consequences, and alternative approaches grounded in evidence rather than ideology.
Punishment, enforcement, and unintended consequences
- UK Home Office & Ministry of Justice data
On drug-related arrests, prosecutions, incarceration, and downstream impacts on reoffending and social outcomes. - The Lancet Commission on Public Health and Drug Policy
Peer-reviewed analysis of how punitive drug laws affect health outcomes, mortality, and inequality.
Potency, markets, and adaptation
- Research on the “iron law of prohibition”
The observed tendency for prohibition to favour more potent substances due to transport and detection incentives. - Studies on New Psychoactive Substances (NPS)
Showing how rapid substance innovation follows enforcement pressure rather than demand growth.
Alternative approaches and comparative evidence
- Portugal’s decriminalisation model
Long-term evidence on drug use rates, overdose deaths, HIV transmission, and criminal justice costs following a shift away from punishment-led policy. - Swiss and Dutch harm-reduction programmes
Evidence on regulated supply, treatment access, and reductions in public harm and system costs.
A final note on intent
Including this material isn’t about winning an argument.
It’s about making clear that the questions raised here aren’t speculative or ideological — they’re grounded in decades of observation, data, and lived outcomes.
You don’t have to agree with the conclusions to recognise the pattern.
And recognising patterns is usually the first step to better policy.
Discover more from Hysnaps Politics, Gaming, Music and Mental Health
Subscribe to get the latest posts sent to your email.
One thought on “Lets Rethink Policy-Making: Drugs”